BEIJING, Oct. 22 (China Economic Net) - A strategic cooperation agreement was signed among Beijing Yuanxin Huibao Technology Co., Ltd., the Pakistan China Business Association, and Nanjing IASO Biotechnology Co.,Ltd., in Beijing on October 17, aiming to promote the accessibility of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy (herein referred as “ CAR-T Therapy”) for adult patients suffering from multiple myeloma in Pakistan.

 

During the signing ceremony, Tahir Farooq, President of Pakistan China Business Association, noted that the partnership will not only introduce advanced CAR-T Therapy to Pakistani patients but also implement innovative payment models to alleviate financial burdens and enhance drug accessibility.

 

Eric Tian, head of overseas operations at IASO Biotechnology, shared insights on how this strategic alliance will leverage each partner's strengths to foster the development of innovative treatment solutions, ultimately providing more efficient CAR-T services for patients in Pakistan.